Ascentage pharma reports 2025 interim unaudited six months financial results and business updates

Rockville, md. and suzhou, china, aug. 20, 2025 (globe newswire) -- ascentage pharma group international (ascentage pharma) (nasdaq: aapg; hkex: 6855) (referred hereinto as “ascentage pharma,” the “company,” “we,” “us” or “our”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today reported its unaudited financial results for the six months ended june 30, 2025, and provided updates on key ongoing clinical programs and commercial activities.
AAPG Ratings Summary
AAPG Quant Ranking